NanoVibronix的ENvue获得儿科饲管引导系统专利，迈向监管批准

Patent strengthens ENvue's IP position as it advances toward pediatric regulatory clearance and expanded clinical use

NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in therapeutic devices, announced today, through its ENvue Medical Holdings LLC division ("ENvue Medical" or "ENvue"), a new U.S. patent for its pediatric feeding tube guidance system. U.S. Patent No. 12,324,632, titled "Insertion Device Positioning Guidance System," further strengthens ENvue Medical's intellectual property portfolio and reflects the Company's ongoing commitment to innovation in feeding tube placement technologies.

This newly granted patent covers ENvue's proprietary system and is designed to assist clinicians in guiding the insertion of feeding tubes in pediatric patients - a population that presents significant anatomical and procedural challenges. This proprietary system is intended to provide real-time navigational data during tube placement, supporting clinical decision-making and potentially reducing reliance on confirmatory imaging.

In the United States alone, approximately 400,000 preterm infants and a large population of additional pediatric patients, including those in intensive care, surgical recovery and chronic care undergo feeding tube placement annually.1-4 Combined, these high-risk groups account for over 1.5 million procedures per year, representing a single U.S. market opportunity of more than $150 million annually in capital systems and disposables5. ENvue's newly granted patent strengthens its ability to serve this critical segment with real-time, precision-guided navigation.